Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre

Published:2019-05 Issue:5 Volume:49 Page:598-606
ISSN:1444-0903
Container-title:Internal Medicine Journal
language:en
Short-container-title:Intern Med J

Author:

Hock Barry D.¹^ORCID,Mulholland Katie S.²,Ganly Peter³,McKenzie Judith L.¹,Pearson John F.⁴,MacPherson Sean A.¹³

Affiliation:

1. Haematology Research Group, Christchurch Hospital and Department of Pathology and Biomedical Science Christchurch New Zealand

2. University of Otago Christchurch New Zealand

3. Haematology Department, Christchurch Hospital Christchurch New Zealand

4. Biostatistics and Computational Biology Unit Christchurch New Zealand

Funder

The Bone Marrow Cancer Research Trust (Christchurch New Zealand).

Publisher

Wiley

Subject

Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/imj.14155

Reference28 articles.

1. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States;Costa LJ;Blood Adv,2017

2. Trends of incidence, mortality, and survival of multiple myeloma in Switzerland between 1994 and 2013;Andres M;Cancer Epidemiol,2018

3. Outcome and survival of myeloma patients diagnosed 2008–2015. Real world data on 4904 patients from the Swedish Myeloma Registry (SMR);Blimark CH;Haematologica,2018

4. Frontline therapy of multiple myeloma;Moreau P;Blood,2015

5. The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe;Cavo M;Expert Rev Hematol,2018

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Māori and Pacific Peoples With Multiple Myeloma in New Zealand are Younger and Have Inferior Survival Compared to Other Ethnicities: A Study From the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR);Clinical Lymphoma Myeloma and Leukemia;2022-08

2. Survival Outcomes of Newly Diagnosed Multiple Myeloma at a Tertiary Care Center in North India (IMAGe: 001A Study);JCO Global Oncology;2021-05

3. Bortezomib use and outcomes for the treatment of multiple myeloma;Internal Medicine Journal;2020-09

4. Clinical outcomes and prognostic factors in patients with multiple myeloma in South Tyrol: a retrospective single-center analysis;Annals of Hematology;2020-03-05

5. Impact of age, sex, ethnicity, socio‐economic deprivation and novel pharmaceuticals on the overall survival of patients with multiple myeloma in New Zealand;British Journal of Haematology;2019-10-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3